Mouwasat Medical Services Company (4002) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached SR 833.8 million, up 9.1% year-over-year, with net profit at SR 209.3 million, a 2.3% increase from Q1 2025.

• Gross profit rose to SR 343.0 million, with a gross margin of 41.2% compared to 43.6% in Q1 2025.

• Earnings per share increased to SR 1.01 from SR 0.99 year-over-year.

Financial highlights

• Medical services revenue grew to SR 710.1 million, and pharmaceutical sales to SR 123.7 million.

• Operating profit was SR 207.0 million, down from SR 213.3 million in Q1 2025.

• Cash flow from operations was SR 304.6 million, up from SR 264.5 million in Q1 2025.

• Total assets increased to SR 6.53 billion from SR 5.99 billion at year-end 2025.

• Total equity rose to SR 4.13 billion, with retained earnings at SR 1.47 billion.

Outlook and guidance

• Management continues expansion with significant capital commitments of SR 371.6 million for ongoing projects.

• No changes in risk management or accounting policies expected to materially impact future results.